41 results on '"van Hoeve, K."'
Search Results
2. Child with protein losing enteropathy as presentation of collagenous duodenitis and eosinophilic gastroenteritis
- Author
-
van Hoeve, K, primary, De Keukelaere, M, additional, De Hertogh, G, additional, and Hoffman, I, additional
- Published
- 2023
- Full Text
- View/download PDF
3. P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
- Author
-
Kantasiripitak, W, primary, WIcha, S G, additional, Thomas, D, additional, Hoffman, I, additional, Ferrante, M, additional, Vermeire, S, additional, van Hoeve, K, additional, and Dreesen, E, additional
- Published
- 2023
- Full Text
- View/download PDF
4. OP032 Outcome of pregnancies in female IBD patients treated with vedolizumab
- Author
-
Moens, A, van Hoeve, K, Humblet, E, Rahier, J -F, Bossuyt, P, Dewit, S, Franchimont, D, Macken, E, Nijs, J, Posen, A, Van Hootegem, A, Van Moerkercke, W, Vermeire, S, and Ferrante, M
- Published
- 2018
- Full Text
- View/download PDF
5. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study
- Author
-
Chaparro, M., Verreth, A., Lobaton, T., Gravito-Soares, E., Julsgaard, M., Savarino, E., Magro, F., Avni Biron, I., Lpez-Serrano, P., Casanova, M., Gompertz, M., Vitor, S., Arroyo, M., Pugliese, D., Zabana, Y., Vicente, R., Aguas, M., Bar-Gil Shitrit, A., Gutierrez, A., Doherty, G., Fernández-Salazar, L., Martinez Cadilla, J., Huguet, J., OʼToole, A., Stasi, E., Manceñido Marcos, N., Villoria, A., Karmiris, K., Rahier, J., Rodriguez, C., Diz-Lois Palomares, M., Fiorino, G., Benítez, J., Principi, M., Naftali, T., Taxonera, C., Mantzaris, G., Sebkova, L., Iade, B., Lissner, D., Ferrer Bradley, I., Lpez-San Román, A., Marín-Jiménez, I., Merino, O., Sierra, M., Van Domselaar, M., Caprioli, F., Guerra, I., Peixe, P., Piqueras, M., Rodríguez-Lago, I., Ber, Y., Van Hoeve, K., Torres, P., Gravito-Soares, E., Rudbeck-Thomsen, D., Bartolo, O., Peixoto, A., Martín, G., Pérez, J., Garre, A., Donday, M.G., Martín de Carpi, J., and Gisbert, J.P.
- Published
- 2017
- Full Text
- View/download PDF
6. P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases
- Author
-
Kantasiripitak, W, primary, van Hoeve, K, additional, Sabino, J, additional, Vermeire, S, additional, Hoffman, I, additional, Declerck, P, additional, Thomas, D, additional, Ferrante, M, additional, and Dreesen, E, additional
- Published
- 2021
- Full Text
- View/download PDF
7. P389 Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with inflammatory bowel disease
- Author
-
van Hoeve, K, primary, Dreesen, E, additional, Hoffman, I, additional, Ferrante, M, additional, and Vermeire, S, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
- Author
-
Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty GA, Fernandez-Salazar L, Martínez Cadilla J, Huguet JM, O'Toole A, Stasi E, Manceñido Marcos N, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, Martín-de-Carpi J, and Gisbert JP
- Abstract
OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.
- Published
- 2018
9. P112 Long-term outcome of immunomodulators use in paediatric patients with inflammatory bowel disease
- Author
-
van Hoeve, K, primary, Hoffman, I, additional, Ferrante, M, additional, and Vermeire, S, additional
- Published
- 2019
- Full Text
- View/download PDF
10. P408 Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
- Author
-
van Hoeve, K, primary, Dreesen, E, additional, Hoffman, I, additional, Ferrante, M, additional, Gils, A, additional, and Vermeire, S, additional
- Published
- 2019
- Full Text
- View/download PDF
11. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
- Author
-
Chaparro, M, primary, Verreth, A, additional, Lobaton, T, additional, Gravito-Soares, E, additional, Julsgaard, M, additional, Savarino, E, additional, Magro, F, additional, Biron, Avni I, additional, Lopez-Serrano, P, additional, Casanova, M J, additional, Gompertz, M, additional, Vitor, S, additional, Arroyo, M, additional, Pugliese, D, additional, Zabana, Y, additional, Vicente, R, additional, Aguas, M, additional, Shitrit, Bar-Gil A, additional, Gutierrez, A, additional, Doherty, G A, additional, Fernandez-Salazar, L, additional, Cadilla, Martínez J, additional, Huguet, J M, additional, O'Toole, A, additional, Stasi, E, additional, Marcos, Manceñido N, additional, Villoria, A, additional, Karmiris, K, additional, Rahier, J F, additional, Rodriguez, C, additional, Palomares, Diz-Lois M, additional, Fiorino, G, additional, Benitez, J M, additional, Principi, M, additional, Naftali, T, additional, Taxonera, C, additional, Mantzaris, G, additional, Sebkova, L, additional, Iade, B, additional, Lissner, D, additional, Bradley, Ferrer I, additional, Roman, Lopez-San A, additional, Marin-Jimenez, I, additional, Merino, O, additional, Sierra, M, additional, Van Domselaar, M, additional, Caprioli, F, additional, Guerra, I, additional, Peixe, P, additional, Piqueras, M, additional, Rodriguez-Lago, I, additional, Ber, Y, additional, van Hoeve, K, additional, Torres, P, additional, Gravito-Soares, M, additional, Rudbeck-Resdal, D, additional, Bartolo, O, additional, Peixoto, A, additional, Martin, G, additional, Armuzzi, A, additional, Garre, A, additional, Donday, M G, additional, de Carpi, Martín F J, additional, and Gisbert, J P, additional
- Published
- 2018
- Full Text
- View/download PDF
12. P169 Infliximab trough levels after induction therapy are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease
- Author
-
van Hoeve, K, primary, Hoffman, I, additional, Dreesen, E, additional, Ferrante, M, additional, Gils, A, additional, and Vermeire, S, additional
- Published
- 2018
- Full Text
- View/download PDF
13. PP15.1 – 2964: Long-term renal outcome of a large cohort of patients with tuberous sclerosis complex
- Author
-
De Waele, L., primary, Van Hoeve, K., additional, Janssens, P., additional, Claes, K., additional, Lagae, L., additional, Levtchenko, E., additional, Bammens, B., additional, Mekahli, D., additional, and Jansen, A., additional
- Published
- 2015
- Full Text
- View/download PDF
14. A BIO-ASSAY TECHNIQUE FOR DETERMINATION OF TRYPANOCYDAL DRUG LEVELS, AND ITS APPLICATION IN ESTIMATING THE DURATION OF ACTIVITY OF BERENIL IN TREATED CATTLE
- Author
-
CUNNINGHAM, M.P., primary, VAN HOEVE, K., additional, and LUMSDEN, W.H.R., additional
- Published
- 1966
- Full Text
- View/download PDF
15. BOVINE TRYPANOSOMIASIS; THE IMMUNE RESPONSE OF THE INFECTED ANIMAL AND THE ANTIGENIC VARIATION OF THE INFECTING ORGANISM
- Author
-
CUNNINGHAM, M.P., primary and VAN HOEVE, K., additional
- Published
- 1966
- Full Text
- View/download PDF
16. A method for the measurement of the infectivity of trypanosome suspensions
- Author
-
Lumsden, W.H.R., primary, Cunningham, M.P., additional, Webber, W.A.F., additional, van Hoeve, K., additional, and Walker, P.J., additional
- Published
- 1963
- Full Text
- View/download PDF
17. Some effects of hydrogen ion concentration on trypanosome numbers and infectivity
- Author
-
Lumsden, W.H.R., primary, Cunningham, M.P., additional, Webber, W.A.F., additional, van Hoeve, K., additional, Knight, R.H., additional, and Simmons, V., additional
- Published
- 1965
- Full Text
- View/download PDF
18. The epidemiology of trypanosoma rhodesiense sleeping sickness in alego location, Central Nyanza, Kenya II. The cyclical transmission of trypanosoma rhodesiense isolated from cattle to a man, a cow and to sheep
- Author
-
van Hoeve, K., primary, Onyango, R.J., additional, Harley, J.M.B., additional, and de Raadt, P., additional
- Published
- 1967
- Full Text
- View/download PDF
19. The epidemiology of Trypanosoma rhodesiense sleeping sickness in alego location, Central Nyanza, Kenya I. Evidence that cattle may act as reservoir hosts of trypanosomes infective to man
- Author
-
Onyango, R.J., primary, van Hoeve, K., additional, and De Raadt, P., additional
- Published
- 1966
- Full Text
- View/download PDF
20. The numbers of infectiveTrypanosoma rhodesienseextruded byGlossina morsitansduring feeding
- Author
-
Harley, J. M. B., primary, Cunningham, M. P., additional, and van Hoeve, K., additional
- Published
- 1966
- Full Text
- View/download PDF
21. Faecal microbiota transplantation in children: A systematic review.
- Author
-
Lauwers E, Sabino J, Hoffman I, and van Hoeve K
- Subjects
- Humans, Child, Gastrointestinal Microbiome, Fecal Microbiota Transplantation methods, Clostridium Infections therapy
- Abstract
Aim: Novel technologies offer insights into the potential role of the intestinal microbiota in human health and disease. Dysbiosis has been associated with several diseases, and it is thought to play a role in the pathogenesis of different gastrointestinal diseases. Faecal microbiota transplantation (FMT) is emerging as a method to modulate the gastrointestinal microbial ecosystem. While recurrent Clostridioides difficile infection is the recognised FMT indication, exploration of other therapeutic uses is ongoing., Methods: Following PRISMA guidelines, we conducted a systematic review, extracting 583 articles from Embase and PubMed (index date to October 2022)., Results: The search yielded 58 studies for full review, with 50 included in the systematic review. Articles were categorised by FMT indication, study design, efficacy, adverse events, donor selection and administration route. FMT appears safe and effective for recurrent Clostridioides difficile infection, although severe adverse events are reported in children. However, there are currently insufficient data to support the use of FMT for other potential therapeutic indications (such as irritable or inflammatory bowel disease or obesity), beside the potential to decolonise multi-drug resistant organisms., Conclusion: This underscores the need for randomised, controlled, prospective cohort studies in children to assess FMT effectiveness in diverse conditions and counteract publication bias., (© 2024 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
22. Nutritional management of high-output ileostomies in paediatric patients is vital and more evidence-based guidelines are needed.
- Author
-
Awouters M, Vanuytsel T, Huysentruyt K, De Bruyne P, Van Hoeve K, and Hoffman I
- Subjects
- Adult, Infant, Newborn, Child, Humans, Energy Intake, Carbohydrates, Electrolytes, Ileostomy adverse effects, Diet
- Abstract
Aim: Paediatric patients with high-output ileostomies (HOI) face an elevated risk of complications. This study aimed to comprehensively review the existing literature and offer nutritional management recommendations for paediatric patients with an HOI., Methods: PubMed and Embase were searched for relevant English or French language papers up to 31 June 2022. The emphasis was placed on studies involving paediatric ileostomy patients, but insights were obtained from adult literature and other intestinal failure pathologies when these were lacking., Results: We identified 16 papers that addressed nutritional issues in paediatric ileostomy patients. Currently, no evidence supports a safe paediatric HOI threshold exceeding 20 mL/kg/day on two consecutive days. Paediatric HOI patients were at risk of dehydration, electrolyte disturbances, micronutrient deficiencies and growth failure. The primary dietary choice for neonates is bolus feeding with breastmilk. In older children, an enteral fluid restriction should be installed favouring isotonic or slightly hypotonic glucose-electrolyte solutions. A diet that is high in calories, complex carbohydrates and proteins, low in insoluble fibre and simple carbohydrates, and moderate in fat is recommended., Conclusion: Adequate nutritional management is crucial to prevent complications in children with an HOI. Further research is needed to establish more evidence-based guidelines., (© 2024 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
23. Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease.
- Author
-
van Hoeve K, Thomas D, Hillary T, Hoffman I, and Dreesen E
- Subjects
- Humans, Female, Child, Tumor Necrosis Factor Inhibitors therapeutic use, Gastrointestinal Agents adverse effects, Remission Induction, Infliximab adverse effects, Risk Factors, Inflammatory Bowel Diseases drug therapy, Crohn Disease drug therapy, Colitis, Ulcerative drug therapy, Skin Diseases chemically induced, Skin Diseases drug therapy
- Abstract
Objectives: While higher infliximab (IFX) trough concentrations (TCs) are associated with better outcomes in patients with inflammatory bowel disease (IBD), they could pose a risk for adverse events (AEs), including IFX-induced skin lesions. Therefore, we studied correlations between IFX TCs and occurrence of AEs in paediatric IBD patients., Methods: In this single-centre study, all children with Crohn's disease (CD) and ulcerative colitis (UC) receiving IFX maintenance therapy who underwent proactive drug monitoring between March 2015 and August 2022 were included. IFX doses/intervals/TCs and patient characteristics were systematically registered, as well as AEs and skin lesions appearance., Results: A total of 109 patients (72 CD and 37 UC) contributed 2913 IFX TCs. During a median follow-up of 3.0 [1.5-4.5] years, we observed 684 AEs in 101 patients and 49 skin lesions in 35 patients. There was no significant difference (p = .467) in median TCs between patients with and without skin lesions. However, higher median IFX doses were associated with an increased hazard rate of skin lesions [HR 1.084 (1.024-1.148), p = .005], in addition to female sex [2.210 (1.187-5.310), p = .016] and diagnosis of CD [1.695 (1.241-1.877), p = .011]. Considering IFX therapeutic TC cut-offs of 5.0 and 9.0 µg/mL, there was no significant difference in AE rate (p = .749 and p = .833, respectively). Also, no significant association between IFX doses and AE rate (p = .159)., Conclusions: Increasing the IFX dose to achieve therapeutic TCs may not increase the overall risk of AEs in paediatric IBD patients. However, concerns arise regarding the risk of skin lesions, especially in female CD patients., (© 2023 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2024
- Full Text
- View/download PDF
24. Nausea is the only symptom associated with delayed gastric emptying in pediatric functional dyspepsia patients.
- Author
-
De Keukelaere M, Carbone F, van Hoeve K, Tack J, and Hoffman I
- Subjects
- Female, Humans, Child, Adolescent, Male, Nausea diagnosis, Abdominal Pain diagnosis, Vomiting, Dyspepsia diagnosis, Gastroparesis
- Abstract
Objectives: Functional dyspepsia (FD) is a heterogeneous functional gastrointestinal disorder (FGID) with a highly prevalent symptom complex. The aim of our study is to investigate the relation between symptoms of FD and results of gastric emptying (GE) breath test in children., Methods: This study included patients (6-17 years old) presented at the general gastroenterology outpatient clinic with dyspeptic symptoms (Rome IV criteria) and underwent careful history taking with clinical examination. A GE breath test with a
13 C-octanoic acid labeled (250 kcal) solid meal was performed and dyspepsia symptom scores, clarified using pictograms for postprandial fullness, bloating, belching, nausea, vomiting, epigastric pain and burning, were obtained every 15 min ranging from 0 to 4 for a total of 240 min. The severity of the complaints (overall and individual symptoms) as displayed by the symptom questionnaire was compared between normal and delayed GE groups. The relationship between GE time and the severity of FD symptoms was assessed using Mann-Whitney test., Results: Thirty nine FD patients (55% girls; mean age: 11.9 ± 3.3 years) participated in the study. Of these, 43% had delayed GE. The overall symptom severity in patients with delayed GE was similar to the symptoms of patients with a normal GE rate (149.5 ± 12.7 points vs. 123.9 ± 9.0; p = 0.19). Individual symptoms scores showed only nausea to be significantly increased in the group with delayed GE (21.5 ± 1.9 points vs. 33.2 ± 4.6; p = 0.048, p < 0.1)., Conclusion: Especially in children with nausea as presenting symptom of FD, a low threshold should be withheld to perform a GE breath test., (© 2023 John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
25. A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
- Author
-
Kantasiripitak W, Wicha SG, Thomas D, Hoffman I, Ferrante M, Vermeire S, van Hoeve K, and Dreesen E
- Subjects
- Child, Humans, Infliximab, Remission Induction, Drug Monitoring methods, Gastrointestinal Agents therapeutic use, Inflammatory Bowel Diseases drug therapy
- Abstract
Background and Aims: Adequate infliximab concentrations during induction treatment are predictive for deep remission [corticosteroid-free clinical and endoscopic remission] at 6 months in children with inflammatory bowel diseases [IBD]. Under standard infliximab induction dosing, children often have low infliximab trough concentrations. Model-informed precision dosing [MIPD; i.e. model-based therapeutic drug monitoring] is advocated as a promising infliximab dosing strategy. We aimed to develop and validate an MIPD framework for guiding paediatric infliximab induction treatment., Methods: Data from 31 children with IBD [4-18 years] receiving standard infliximab induction dosing (5 mg/kg at week [w]0, w2 and w6) were repurposed. Eight paediatric population pharmacokinetic models were evaluated. Modelling and simulation were used to identify exposure targets, identify an optimal sampling strategy, and develop a multi-model prediction algorithm for implementation into an MIPD software tool. A role for infliximab clearance monitoring was evaluated., Results: A 7.5 mg/L infliximab concentration target at w12 was associated with 64% probability of deep remission at 6 months. With standard dosing, less than 80% of simulated children <40 kg attained this target. The w12 target was most accurately and precisely achieved by implementing MIPD at w6 using the w6 infliximab concentration [rapid assay required]. The multi-model algorithm outperformed single models when optimizing the w6 dose based on both w2 and w4 concentrations. MIPD using only the w2 concentration resulted in biased and imprecise predictions. Infliximab clearances at w6 and w12 were predictive for deep remission., Conclusions: A freely available, multi-model MIPD tool facilitates infliximab induction dosing and improves deep remission rates in children with IBD., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
26. Child with protein losing enteropathy as presentation of collagenous duodenitis and eosinophilic gastroenteritis.
- Author
-
van Hoeve K, De Keukelaere M, De Hertogh G, and Hoffman I
- Subjects
- Humans, Female, Child, Preschool, Serum Albumin, Histamine Antagonists administration & dosage, Proton Pump Inhibitors therapeutic use, Diarrhea etiology, Edema etiology, Protein-Losing Enteropathies diagnosis, Gastritis diagnosis, Gastritis drug therapy, Duodenitis diagnosis, Duodenitis drug therapy
- Abstract
Background: Collagenous duodenitis and gastritis are rare histopathological findings in children., Patients and Methods: : We describe a four-year old girl, who presented with non-bloody diarrhea for two months and progressive edema with an albumin of 16g/dl., Results: The diagnosis of a protein losing enteropathy was made. Extensive investigations withheld only an infectious cause of the protein losing enteropathy (cytomegalovirus and adenovirus). However, the patients still required repetitive albumin infusions 3.5 months after onset of symptoms without spontaneous recovery. Therefore, a new endoscopic work-up was performed. Duodenal biopsies revealed collagen deposition, in association with a high number of eosinophils and mast cells throughout different parts of the gastrointestinal tract., Conclusions: The collagen deposition seems to be triggered by an eosinophilic gastrointestinal disorder. Treatment was started with amino acid-based formula, oral iron therapy, an antihistamine, and a proton pomp inhibitor that resulted in persistent normalization of serum albumin already after 1.5 weeks., Competing Interests: The authors declare that they have no conflict of interest, (© Acta Gastro-Enterologica Belgica.)
- Published
- 2023
- Full Text
- View/download PDF
27. Renal manifestations in inflammatory bowel disease: a systematic review.
- Author
-
van Hoeve K and Hoffman I
- Subjects
- Adult, Humans, Inflammatory Bowel Diseases drug therapy
- Abstract
As extra-intestinal manifestations (EIMs) are frequent in inflammatory bowel disease (IBD) and affect morbidity and sometimes even mortality, vigilance in the surveillance of EIMs and installing the appropriate treatment are essential. Data on renal manifestations in patients with IBD are however rare. Nevertheless, up to 5-15% of adult patients with IBD will develop chronic kidney disease over time. The pathophysiology of renal involvement in patients with IBD is complex and poorly understood, with a wide range of renal disorders affecting the glomeruli and/or the tubular structure. Furthermore, medication used to treat IBD can be potentially nephrotoxic and metabolic complication due to the disease itself can furthermore cause renal damage. The aim of this systematic review is to provide an overview of the existing data in literature on these renal manifestations and complications in patients with IBD., (© 2022. Japanese Society of Gastroenterology.)
- Published
- 2022
- Full Text
- View/download PDF
28. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.
- Author
-
van Hoeve K, Seyed Tabib NS, Dreesen E, Tops S, Hoffman I, Gils A, Ferrante M, and Vermeire S
- Subjects
- Adolescent, Child, Child, Preschool, Drug Monitoring, Female, Follow-Up Studies, Gastrointestinal Agents therapeutic use, Humans, Infliximab therapeutic use, Male, Prospective Studies, Endoscopy, Digestive System, Gastrointestinal Agents blood, Inflammatory Bowel Diseases drug therapy, Infliximab blood, Remission Induction
- Abstract
Objectives: To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel disease (IBD) during induction therapy to predict outcome and explore if other covariates influenced outcome., Study Design: All children with IBD starting IFX therapy (5 mg/kg at weeks 0, 2, 6, and 12) for active luminal disease from May 2017 to May 2019 were included and followed prospectively. Patients were sampled at multiple timepoints during induction (trough concentrations and peak concentration at weeks 0, 2, 6, and 12, and intermediate concentration at weeks 1-4). IFX concentrations and cumulative drug exposure were correlated with outcome at 6 months. Endoscopic remission was defined as Simple Endoscopic Score for Crohn's Disease of <3 or Mayo endoscopic subscore of 0, and deep remission as endoscopic with clinical remission (Pediatric Ulcerative Colitis Activity Index/Pediatric Crohn's Disease Activity Index of <10)., Results: There were 252 serum induction concentrations obtained from 32 patients (81% on concomitant thiopurines). Children in endoscopic remission (all in deep remission) at 6 months had significantly higher drug concentrations from week 4 onward. A receiver operating characteristics curve analysis identified IFX trough concentrations at week 12 of ≥5.0 μg/mL and area under the curve at weeks 0-12 of ≥4056.0 μg∗day/mL as the minimal target to achieve endoscopic remission at 6 months (area under the receiver operating characteristics curve, 0.796 [95% CI, 0.62-0.97] and area under the receiver operating characteristics curve, 0.778 [95% CI, 0.61-0.94], respectively). In addition, our findings suggest that proteomic analysis may help to understand IFX response., Conclusions: Higher IFX exposure during induction therapy in pediatric patients with IBD is associated with significantly better endoscopic and deep remission rates at 6 months. Drug concentrations differentiate remitters from nonremitters from week 4 after induction onward., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
29. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place.
- Author
-
van Hoeve K and Vermeire S
- Subjects
- Child, Drug Therapy, Combination, Humans, Immunologic Factors adverse effects, Purines adverse effects, Thionucleosides adverse effects, Biological Products therapeutic use, Immunologic Factors therapeutic use, Inflammatory Bowel Diseases drug therapy, Purines therapeutic use, Thionucleosides therapeutic use
- Abstract
Thiopurines have been widely used to maintain steroid-free remission in children with inflammatory bowel disease (IBD). However, within the expanding treatment armamentarium, the role of these non-selective immunomodulators has been questioned, especially in pediatric patients, who often present with a more aggressive disease course, which can impact growth and development. The less favorable safety but also inferior efficacy profile associated with thiopurines, in contrast to the newer biological therapies, has interfered with their use. The future place of thiopurines in the management of childhood IBD, therefore, needs revisiting. This review provides a practical overview on the historical and current use of thiopurines in pediatric IBD with specific attention for thiopurine S-methyltransferase testing and monitoring of thiopurine metabolite levels as an approach to improve outcomes. We also give a personal expert opinion on the future role of these drugs in childhood IBD.
- Published
- 2020
- Full Text
- View/download PDF
30. Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease.
- Author
-
van Hoeve K, Hoffman I, D'Hoore A, Ferrante M, and Vermeire S
- Subjects
- Adolescent, Biological Products therapeutic use, Child, Female, Humans, Male, Proportional Hazards Models, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Immunologic Factors therapeutic use
- Abstract
Objectives: In the era where new biologicals are entering the market, the place of immunomodulators in the treatment of pediatric inflammatory bowel disease (IBD) needs to be reassessed., Methods: All children with Crohn's disease (CD) or ulcerative colitis (UC) followed at our center over the last 10 years were reviewed. Children who received conventional therapy (including 5-aminosalicylates, steroids, thiopurines and methotrexate) since diagnosis were included. Primary outcome was steroid-free clinical remission without need for rescue therapy (biologics or surgery) at 6 and 12 months after diagnosis and at last follow-up. Cox proportional hazard modelling was performed to determine variables at diagnosis associated with outcomes., Results: In total, 176 IBD patients (121 CD, 55 UC) were identified with a median follow-up of 4.6 [2.0-8.1] years. Remission rates were 79.6% at month 6, but decreased to 60.2% at month 12, and 31.8% at last follow-up. Higher CRP [1.006 (1.001-1.011)], lower albumin [1.050 (1.012-1.086)] and growth impairment [1.214 (1.014-1.373)] in CD patients and higher PUCAI score [1.038 (1.006-1.072)] and low iron [1.023 (1.003-1.043)] in UC patients were associated with treatment failure (all p < 0.05)., Conclusion: Only 32% pediatric IBD patients will remain free of biologics or surgery 5-years after diagnosis. Especially children with a high disease burden at diagnosis were more likely to fail conventional therapy., (Copyright © 2019. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
31. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
- Author
-
van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, and Vermeire S
- Subjects
- Adolescent, Biomarkers blood, Child, Colitis, Ulcerative blood, Crohn Disease blood, Female, Follow-Up Studies, Gastrointestinal Agents blood, Humans, Induction Chemotherapy, Infliximab blood, Infusions, Intravenous, Logistic Models, Maintenance Chemotherapy, Male, Predictive Value of Tests, Prospective Studies, Retrospective Studies, Time Factors, Treatment Outcome, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Drug Monitoring statistics & numerical data, Gastrointestinal Agents administration & dosage, Infliximab administration & dosage
- Abstract
Objectives: Therapeutic drug monitoring has been proposed as a useful tool in the management of infliximab (IFX) treated patients with inflammatory bowel disease. The aim of this retrospective study was to determine whether IFX trough levels after induction therapy are predictive for outcome at week 52., Methods: All pediatric patients with inflammatory bowel disease receiving maintenance IFX at our centre, with IFX trough level available at their first maintenance infusion and a follow-up of at least 52 weeks were included. IFX induction regimens could be intensified at the discretion of the treating physician. All children received proactive drug monitoring during maintenance with dose adaptation aiming to target a therapeutic window of 3 to 7 μg/mL., Results: We included 35 children (23 with Crohn disease and 12 with ulcerative colitis). Median IFX trough levels just before the first maintenance infusion were significantly higher in children achieving clinical (4.6 μg/mL [2.7-11.8] vs 1.5 μg/mL [0.9-3.0]), biological (4.6 μg/mL [2.5-10.3] vs 2.6 μg/mL [0.3-3.2]) and combined clinical/biological remission (6.0 μg/mL [3.2-12.0] vs 2.6 μg/mL [1.1-3.2]) at week 52 compared to children not meeting these criteria (all P ≤ 0.002). Binary logistic regression identified these trough levels as the only predictor for the same outcomes with an odds ratio (95% confidence interval) of 2.083 (1.085-3.998), 2.203 (1.101-4.408), and 2.264 (1.096-4.680), respectively (all P < 0.05)., Conclusions: Adequate IFX exposure during induction therapy is associated with better clinical and/or biological remission at week 52. Postinduction IFX trough levels were the only predictor for clinical and/or biological remission at week 52.
- Published
- 2019
- Full Text
- View/download PDF
32. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
- Author
-
van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, and Vermeire S
- Subjects
- Adolescent, Antibodies, Monoclonal pharmacology, C-Reactive Protein metabolism, Child, Colitis, Ulcerative drug therapy, Colitis, Ulcerative metabolism, Crohn Disease drug therapy, Crohn Disease metabolism, Drug Substitution methods, Female, Gastrointestinal Agents therapeutic use, Humans, Inflammatory Bowel Diseases metabolism, Male, Prospective Studies, Treatment Outcome, Biosimilar Pharmaceuticals therapeutic use, Inflammatory Bowel Diseases drug therapy, Infliximab therapeutic use
- Abstract
Background: Rising evidence demonstrates that there are no differences in efficacy and safety between infliximab (IFX) originator and IFX biosimilar CT-P13 in the treatment of inflammatory bowel diseases (IBDs). However, most data are derived from adult patients, and data on pharmacokinetics are limited. The authors evaluated long-term IFX trough levels, immunogenicity, and remission rates in children with IBD who switched from IFX originator to biosimilar CT-P13., Methods: In this single-center study, all children with Crohn disease and ulcerative colitis receiving maintenance IFX therapy were switched from originator to biosimilar CT-P13. Demographics, disease activity indices, and IFX drug levels were collected from 6 months before (baseline) till 6 months after switching to CT-P13. All data are presented as median (interquartile range)., Results: A total of 42 children (26 Crohn disease and 16 ulcerative colitis), with a median duration on IFX originator of 13.5 (6.8-35.5) months before switching to CT-P13, were included. No significant changes in IFX trough levels occurred after switching. The median baseline IFX trough level was 5.7 mcg/mL (3.8-9.3) versus 6.5 mcg/mL (3.9-8.6) at month 6 after switching (P = 0.900). Antibodies to IFX appeared in one patient after switching. The proportion of patients in clinical and/or biological remission did not significantly change after switching (all P > 0.05). No significant changes were observed in C-reactive protein, erythrocyte sedimentation rate, albumin, weight, and body mass index after the switch. Safety profile was also comparable., Conclusions: Pediatric patients with IBD on IFX originator can be successfully switched during maintenance to biosimilar CT-P13 without affecting efficacy, pharmacokinetics, immunogenicity, or safety.
- Published
- 2019
- Full Text
- View/download PDF
33. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.
- Author
-
Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, Strubbe B, Van Hootegem A, Van Moerkercke W, Vermeire S, and Ferrante M
- Subjects
- Abortion, Spontaneous epidemiology, Adult, Apgar Score, Belgium epidemiology, Birth Weight, Congenital Abnormalities epidemiology, Female, Fetal Growth Retardation epidemiology, Gestational Age, Humans, Infant, Newborn, Infant, Small for Gestational Age, Live Birth epidemiology, Pregnancy, Premature Birth epidemiology, Retrospective Studies, Severity of Illness Index, Stillbirth epidemiology, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Gastrointestinal Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Pregnancy Complications epidemiology, Pregnancy Outcome epidemiology
- Abstract
Background and Aims: Vedolizumab is an IgG1 anti-α4β7 integrin antibody approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucosal vascular addressin cell adhesion molecule 1 [MAdCAM-1] is expressed by maternal vessels in the placenta and recruits α4β7-expressing cells that are considered important for maternal/fetal tolerance. Blocking this interaction by vedolizumab might affect this process. We aimed to evaluate pregnancy outcomes in vedolizumab-treated female IBD patients., Methods: We conducted a retrospective, multicentre Belgian observational study. Details on disease activity, prenatal complications, delivery and neonatal outcome were collected through a case report form., Results: Twenty-four pregnancies were reported. Five women had active disease at conception and one patient flared during pregnancy. There were 23 live births. Complications were observed in 25% of pregnancies [premature rupture of membranes, pre-eclampsia, miscarriage, elective termination and stillbirth] and in 35% of infants [prematurity, intra-uterine growth retardation, small for gestational age and congenital malformations including hip dysplasia, pulmonary valve stenosis and Hirschprung's disease]. Vedolizumab was continued throughout pregnancy in two females and stopped in the 1st and 2nd trimester in five and 16 patients, respectively. For live born children, the median [interquartile range] gestational age, weight and Apgar score 5 min after birth were 39 [37-39.6] weeks, 3270 [3080-3585] grams and 10 [9-10], respectively., Conclusions: Although several complications were observed, both in mothers and in newborns, no firm conclusions can be drawn. Awaiting prospective and controlled registries, vigilance and strict follow-up of pregnant patients treated with vedolizumab seems mandatory.
- Published
- 2019
- Full Text
- View/download PDF
34. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
- Author
-
van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, and Vermeire S
- Subjects
- Adolescent, C-Reactive Protein metabolism, Child, Colitis, Ulcerative diagnostic imaging, Crohn Disease diagnostic imaging, Drug Monitoring, Endoscopy, Gastrointestinal, Female, Gastrointestinal Agents administration & dosage, Humans, Infliximab administration & dosage, Maintenance Chemotherapy, Male, Recurrence, Remission Induction, Retrospective Studies, Treatment Outcome, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Gastrointestinal Agents blood, Gastrointestinal Agents therapeutic use, Infliximab blood, Infliximab drug effects
- Abstract
Background: The role of therapeutic drug monitoring for infliximab [IFX] therapy in children with inflammatory bowel disease [IBD] is poorly investigated. We determined if IFX exposure correlates with long-term remission in children., Methods: In this retrospective study, all children with Crohn's disease [CD] and ulcerative colitis [UC], receiving maintenance IFX at our centre, were included. Serum trough levels and cumulative drug exposure were correlated with clinical, biological, and endoscopic remission. All children received proactive drug monitoring and dose adaptation aiming to target a therapeutic window of 3-7 µg/mL. All data are presented as median [interquartile range]., Results: A total of 686 serum levels during IFX maintenance in 52 paediatric patients [33 CD and 19 UC] were included (median 9 [4-18] per patient). With a median of 17 [8-36] months under IFX therapy, 39/52 [75%] patients were in clinical remission and 29/40 [73%] patients were in endoscopic remission. Median IFX trough levels were significantly higher when children achieved clinical remission (5.4 [3.8-8.0] µg/mL versus 4.2 [2.6-6.7] µg/mL), biological remission (5.2 [3.7-7.7] µg/mL versus 4.2 [2.6-6.5] µg/mL), combined clinical and biological remission (5.7 [4.0-8.2] µg/mL versus 4.4 [2.7-6.8] µg/mL) and endoscopic remission (6.5 [4.2-9.5] µg/mL versus 3.2 [2.3-5.6] µg/mL) compared with not meeting these criteria [all p ≤ 0.001]., Conclusions: In this large paediatric cohort, children with clinical and/or endoscopic remission had significantly higher IFX exposure during maintenance therapy. We showed excellent outcome data using serial and systematic measurements of drug levels. This could provide a rationale for the use of proactive drug monitoring in children in order to improve long-term outcomes.
- Published
- 2018
- Full Text
- View/download PDF
35. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.
- Author
-
Janssens P, Van Hoeve K, De Waele L, De Rechter S, Claes KJ, Van de Perre E, Wissing KM, Bammens B, Jansen A, and Mekahli D
- Subjects
- Adolescent, Adult, Aged, Angiomyolipoma epidemiology, Angiomyolipoma etiology, Angiomyolipoma pathology, Child, Child, Preschool, Disease Progression, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypertension epidemiology, Hypertension etiology, Hypertension pathology, Infant, Infant, Newborn, Kidney pathology, Kidney Diseases, Cystic epidemiology, Kidney Diseases, Cystic etiology, Kidney Diseases, Cystic pathology, Kidney Failure, Chronic etiology, Kidney Failure, Chronic pathology, Kidney Neoplasms epidemiology, Kidney Neoplasms etiology, Kidney Neoplasms pathology, Male, Middle Aged, Prevalence, Proteinuria epidemiology, Proteinuria etiology, Proteinuria pathology, Retrospective Studies, Risk Factors, Young Adult, Kidney Failure, Chronic epidemiology, Tuberous Sclerosis complications
- Abstract
Background: Renal pathology in tuberous sclerosis complex (TSC) is characterized by the growth of angiomyolipoma and renal cysts, and in rare cases renal cell carcinoma. Other consequences of renal involvement in TSC, including hypertension, proteinuria, and hyperfiltration, are not well studied. We aimed to analyze the early manifestations of the renal TSC phenotype in a young TSC cohort and to explore common, modifiable risk factors., Methods: In this retrospective cohort study, TSC patients attending the TSC clinics of two tertiary hospitals were included. Data on demographics, history, genotype, kidney function, hematuria, proteinuria, blood pressure, and renal imaging were collected., Results: Eighty patients were included, with a median age of 0.8 years (0.0-63.0) at first presentation, and a median follow-up time of 10.2 (0.4-41.0) years. Mutation analysis was available in 64 patients (80%). Renal lesions (cysts or angiomyolipoma) were observed in 55/73 (75%). Thirty-two percent (19/60) were hypertensive, 8/51 (16%) had proteinuria, and 18/71 (25%) had hyperfiltration (median eGFR 154 ml/min/m
2 ). Six (7.5%) patients had developed end stage renal disease at the last follow-up. No association was found between hyperfiltration, hypertension, or proteinuria and CKD ≥ 3. Cox regression showed a significant positive association between the presence of a renal intervention and CKD ≥ 3 (Hazard-Ratio 3.91, P < 0.05)., Conclusions: Besides renal cysts and angiomyolipoma, the modifiable progression factors hypertension, proteinuria, and hyperfiltration occur frequently and early in TSC patients. This represents a preventive treatment target.- Published
- 2018
- Full Text
- View/download PDF
36. Liver involvement in kidney disease and vice versa.
- Author
-
Van Hoeve K, Mekahli D, Morava E, Levtchenko E, and Witters P
- Subjects
- Child, Humans, Kidney Diseases therapy, Kidney Transplantation methods, Liver Diseases therapy, Liver Transplantation methods, Kidney physiopathology, Kidney Diseases complications, Liver physiopathology, Liver Diseases complications
- Abstract
The liver and kidneys are often similarly affected by a single disease. This is the case in metabolic, immunological, toxic, and infectious diseases, and in the different congenital malformation syndromes. Also, an enzymatic defect in an otherwise healthy liver or the consequences of advanced liver disease by itself can cause kidney disease as a secondary phenomenon. In this review, we describe numerous pathogenic mechanisms leading to dysfunction or malformations of the liver and kidneys in children. We encourage multidisciplinary management for optimal care. A combined liver-kidney transplantation is sometimes needed.
- Published
- 2018
- Full Text
- View/download PDF
37. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
- Author
-
van Hoeve K, Hoffman I, and Vermeire S
- Subjects
- Adult, Child, Gastrointestinal Agents administration & dosage, Gastrointestinal Agents adverse effects, Gastrointestinal Agents pharmacology, Humans, Treatment Outcome, Drug Monitoring methods, Inflammatory Bowel Diseases drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Introduction: Although anti-TNF therapy has changed the scenery of pediatric inflammatory bowel diseases (IBD) immensely, there are still patients with an unfortunate outcome. Approximately one third of patients that initially respond to anti-TNF therapy will lose that response over time and need treatment optimization. Loss of response (LOR) is a big concern in IBD management and especially among pediatric patients where treatment options are more limited than in adults. In children it is even more important to sustain response with minimal toxicity. Therapeutic drug monitoring (TDM) is proposed as a tool to reach this goal., Areas Covered: This review focuses on the importance of TDM of anti-TNF and the role TDM has in clinical practice of pediatric IBD., Expert Opinion: Although TDM is not yet widely used in pediatric IBD, the available literature suggests it to be a promising tool, especially in patients with LOR to anti-TNF. There is increasing evidence that also in children, higher anti-TNF drug levels are associated with sustained response, and likewise low or undetectable trough levels increase the likelihood of LOR. TDM-based treat to target strategies are being designed in adult studies, but more prospective studies also in pediatric IBD populations looking at the role of proactive testing are needed.
- Published
- 2018
- Full Text
- View/download PDF
38. Occurrence of atypical HUS associated with influenza B.
- Author
-
van Hoeve K, Vandermeulen C, Van Ranst M, Levtchenko E, van den Heuvel L, and Mekahli D
- Subjects
- Adolescent, Atypical Hemolytic Uremic Syndrome blood, Atypical Hemolytic Uremic Syndrome therapy, Biomarkers blood, Child, Humans, Male, Mutation, Plasma Exchange, Recurrence, Atypical Hemolytic Uremic Syndrome genetics, Creatine blood, Influenza B virus genetics
- Abstract
Hemolytic uremic syndrome (HUS) is a disease characterized by thrombotic microangiopathy with a triad of non-immune hemolytic anemia, thrombocytopenia, and renal impairment. Approximately 10% of cases of HUS are classified as atypical (aHUS). While today many genetically forms of aHUS pathology are known, only about 50% of carriers precipitate the disease. The reason remains unclear, and triggering events like intercurrent infections have been postulated. In rare cases, influenza A is the known trigger of aHUS; however, no cases of influenza B have been reported., Conclusion: We describe for the first time that influenza B strain as a trigger for aHUS in children with primary hereditary forms. We also showed in our three cases that immunization appears to be safe; however, this needs to be confirmed in a larger cohort. What is Known: • Known triggers of aHUS are infectious specimen. • Influenza A-associated aHUS cases are rarely published. What is New: • aHUS can be triggered by influenza B virus infection. • Influenza vaccination of patients with aHUS appears safe.
- Published
- 2017
- Full Text
- View/download PDF
39. Microvillus inclusion disease: a subtotal enterectomy as a bridge to transplantation.
- Author
-
van Hoeve K, Hoffman I, Fusaro F, Pirenne J, Vander Auwera A, Dieltjens AM, De Hertogh G, Monbaliu D, and Miserez M
- Subjects
- Biopsy, Follow-Up Studies, Humans, Infant, Newborn, Intestines diagnostic imaging, Malabsorption Syndromes diagnosis, Male, Mucolipidoses diagnosis, Time Factors, Digestive System Surgical Procedures methods, Intestines surgery, Malabsorption Syndromes surgery, Microvilli pathology, Mucolipidoses surgery, Organ Transplantation
- Abstract
Background: Microvillus inclusion disease (MVID) is a known congenital cause of intractable diarrhea resulting in permanent intestinal failure. There is need for a lifelong total parenteral nutrition (TPN) from diagnosis and the prognosis is poor. Most patients die by the second decade of life as a result of complications of parenteral alimentation including liver failure or sepsis. The only available treatment at this moment is a small bowel transplantation. But before that moment, the patients often suffer from a persistent failure to thrive and electrolyte disturbances despite continuous TPN., Methods and Results: We report what we believe is a first case of an extensive small bowel resection in a 5-month-old boy with proven MVID to act as a bridge to (liver-) intestinal transplantation to treat failure to thrive and intractable diarrhea., Conclusions: An extensive small bowel resection can be done to enhance the chance of survival leading up to the transplantation by managing fluid and electrolyte imbalance. It facilitates medical management of these patients and makes a bowel transplantation possible at a later stage.
- Published
- 2016
- Full Text
- View/download PDF
40. Necessity of fractionated urine collection for monitoring patients with cystinuria.
- Author
-
van Hoeve K, Vermeersch P, Regal L, and Levtchenko E
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Urinalysis, Young Adult, Cystine analysis, Cystinuria urine, Monitoring, Physiologic methods, Specimen Handling methods
- Published
- 2011
- Full Text
- View/download PDF
41. Survey on blood parasites of cattle presented for treatment against trypanosomiasis in Nigeria.
- Author
-
Folkers C, Buys J, Blotkamp J, Kuil H, and Van Hoeve K
- Subjects
- Anaplasmosis epidemiology, Anaplasmosis veterinary, Animals, Babesiosis epidemiology, Babesiosis veterinary, Cattle, Nigeria, Protozoan Infections epidemiology, Theileriasis veterinary, Cattle Diseases epidemiology, Protozoan Infections, Animal, Trypanosomiasis, Bovine epidemiology
- Published
- 1970
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.